about
Harnessing the potential of community-based participatory research approaches in bipolar disorderThe Default Mode Network in Healthy Individuals: A Systematic Review and Meta-Analysis.Innovations in the Management of Musculoskeletal Pain With Alpha-Lipoic Acid (IMPALA Trial): Study protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Alpha-Lipoic Acid for the Treatment of Fibromyalgia PainMicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.Pain Improvement With Novel Combination Analgesic Regimens (PAIN-CARE): Randomized Controlled Trial ProtocolSwitch to mania upon discontinuation of antidepressants in patients with mood disorders: a review of the literature.Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial.Response of depression to botulinum toxin treatment: agitation as a predictorClinical outcome and memory function with maintenance electroconvulsive therapy: a retrospective study.Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies.Effects of electroconvulsive therapy and repetitive transcranial magnetic stimulation on serum brain-derived neurotrophic factor levels in patients with depression.Stigma and discrimination in people suffering with a mood disorder: a cross-sectional study.Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Effects, experiences, and impact of stigma on patients with bipolar disorderA review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder.Transcranial Magnetic Stimulation of the Supplementary Motor Area in the Treatment of Obsessive-Compulsive Disorder: A Multi-Site Study.Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Introduction and MethodsCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.Sleep architecture in ziprasidone-treated bipolar depression: a pilot study.The effects of probiotics on depressive symptoms in humans: a systematic review.The neurobiology of the EEG biomarker as a predictor of treatment response in depression.The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future.Delivery of electroconvulsive therapy in Canada: a first national survey report on usage, treatment practice, and facilities.Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid - Pregabalin Combination for the Treatment of Fibromyalgia PaStandardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression.Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment.Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial.The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction.Comparison of stigmatizing experiences between Canadian and Korean patients with depression and bipolar disorders.Erratum to: The effects of probiotics on depressive symptoms in humans: a systematic review.Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression GuidelinesOlfactory Functioning and Depression: A Systematic Review.Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression.
P50
Q30384240-0A8AAEC1-040A-44D9-89BB-8BAEA3A21583Q31146862-4A38E996-78B2-4C44-A493-32553C40F83AQ33555352-1C136BDF-5867-41F9-9E82-72C1178AD3AAQ33815733-A9EDAD58-51F7-406C-A9D8-612F05714C3DQ33826759-3702FF65-2CA4-4A4E-A5F7-C96192FB3150Q34201451-AC1B3661-7A62-4463-88DF-FABF32161439Q34468541-0DE9E6BE-09D4-4623-B9CF-0F3B66539E43Q34475052-7E095E49-6B2F-4FEF-9807-1E7710CCD418Q34516790-CC5AD8F4-F0B9-493F-A4B8-0D41DCAEF5FFQ34995758-E104E974-02F4-4BC2-BD03-33CD007DD777Q35775727-3F24B34E-14A4-4DB3-BD32-4EED7F2C664FQ35895672-F41B9B97-693A-49AD-AC61-0C4DD5A8C6D7Q35991586-2D14954B-1A9D-49D8-BEDD-8E62D9CC4FDDQ36161335-CA90FAC1-CA7C-42BC-A650-8F8C6564BF97Q36555352-4B2F7779-B24E-46B4-BB4B-39277EAA9CD4Q36555366-BE4665D5-7BCB-4E79-8A90-37C3EA1679E1Q36743828-BDC32542-CFEC-430C-910D-51217F272565Q37124973-534604AE-9BC9-4127-BD2C-440F44A2B264Q37197203-15A56189-50CB-4077-A5A0-DFB788FB37C1Q37197207-E1D47C76-814B-4465-AB00-AB5140367743Q37197211-3F948D31-F230-45EE-B701-C3287A51B1C4Q37197216-4887F782-6CE6-4A47-AB94-983EAB0C3F0EQ37197221-4787CA77-1463-4CC7-80B6-141074C9059DQ37197224-66065977-CA0C-41EE-B491-CD8E9CC5C0DDQ37197230-4532D9ED-87F6-4E5C-8806-E846DEE9BB7DQ37248118-D6678699-EC52-41CE-A00F-F212DDDC8E14Q37655518-B7AD8E2D-CA85-4669-8BC4-8DB01FE5E119Q38008514-8BA5A422-C673-4BB2-8979-5B1E832EB369Q38075910-4C99ACAF-6816-4AB1-BE29-14A697A64483Q38263620-D34B6569-5204-4BC0-8DD0-76D5F9F30AC9Q38372555-BF16BD67-9AA4-4555-8660-804E1308F040Q38636012-B5543CC5-5D03-43CD-BFAE-309EE22D8505Q39005420-845F9AF8-39BC-4455-9BB3-A27E572D9F3AQ39175289-5FA6DA2C-988D-4D3E-BEE7-DA90C4433B02Q39605843-A86C8DAB-90A4-49BD-8FF7-949E26BB3AC3Q41371212-6E5C0DD1-19DA-4437-B77E-4B5D608256B8Q42317644-C6383702-314B-405B-A4C5-54E775DA0BDCQ42322408-158992E5-437B-4788-AACF-8BFBD4E1DAF3Q42369920-1E0289F8-2C0E-46D9-8B12-384BFD735816Q42590585-48B5660A-57B6-440F-BF0E-3124DB383218
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roumen Milev
@ast
Roumen Milev
@en
Roumen Milev
@es
Roumen Milev
@nl
Roumen Milev
@sl
type
label
Roumen Milev
@ast
Roumen Milev
@en
Roumen Milev
@es
Roumen Milev
@nl
Roumen Milev
@sl
prefLabel
Roumen Milev
@ast
Roumen Milev
@en
Roumen Milev
@es
Roumen Milev
@nl
Roumen Milev
@sl
P1053
F-4521-2012
P106
P1153
12784225100
57192179049
P21
P2798
P31
P3829
P496
0000-0001-6884-171X